Femasys (FEMY) Cash from Financing Activities (2020 - 2026)
Femasys' (FEMY) quarterly Cash from Financing Activities came in at $342334.0 in Q1 2026, down 93.45% YoY from $5.2 million in Q1 2025, and down 96.23% on a QoQ basis from $9.1 million in Q4 2025.
Femasys (FEMY) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Femasys (FEMY) has 7 years of Cash from Financing Activities data on file, last reported at $342334.0 in Q1 2026.
- Quarterly Cash from Financing Activities fell 93.45% year-over-year to $342334.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.2 million (up 212.48% YoY) and the FY2025 annual result came in at $25.1 million, up 1139.74% from the prior year.
- Cash from Financing Activities slipped to $342334.0 in Q1 2026, from $9.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $16.1 million in Q4 2023 to a low of -$362039.0 in Q3 2022.
- A 5-year average of $2.9 million and a median of $824252.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.32% — and 2023, when it surged 19751.64%.
- Tracing FEMY's Cash from Financing Activities over 5 years: stood at -$81950.0 in 2022, then surged by 19751.64% to $16.1 million in 2023, then sank by 93.63% to $1.0 million in 2024, then surged by 785.15% to $9.1 million in 2025, then plunged by 96.23% to $342334.0 in 2026.
- The last three Cash from Financing Activities figures came in at $342334.0 (Q1 2026), $9.1 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Femasys | 9.97 Mn | 8.53 Mn | 189,391.00 | 15,329.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 342,334.00 |
| Mar 31, 2026 | 342,334.00 |
| Dec 31, 2025 | 9.08 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Sep 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 3.85 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Mar 31, 2025 | 5.23 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Jun 30, 2024 | 223,549.00 |
| Jun 30, 2024 | 223,549.00 |
| Mar 31, 2024 | 778,175.00 |
| Mar 31, 2024 | 778,175.00 |
| Dec 31, 2023 | 16.10 Mn |
| Dec 31, 2023 | 16.10 Mn |
| Sep 30, 2023 | 870,329.00 |
| Sep 30, 2023 | 870,329.00 |